Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 77 matching trials from the live ClinicalTrials.gov search.
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Active, not recruiting Phase 3 Interventional

Vafseo Outcomes In-Center Experience

NCT06520826
Conditions
Anemia of Chronic Kidney Disease
Interventions
Vadadustat, Erythropoiesis Stimulating Agent
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Conditions
Anemia
Interventions
darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Los Angeles, California • Mather, California • Stanford, California + 18 more
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

NCT05078138
Conditions
Exercise-Induced Anemia, Physical Performance
Interventions
Epoetin Alfa
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY 85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Azusa, California • Long Beach, California • Los Angeles, California + 21 more
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Anemia
Interventions
Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Azusa, California • Los Angeles, California • Whittier, California + 16 more
Conditions
Anemia in Incident Dialysis Patients
Interventions
Roxadustat, Epoetin Alfa
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Chula Vista, California • La Mesa, California • San Diego, California + 25 more
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Anaemia
Interventions
Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Interventions
PROCRIT 40,000 IU QW, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Conditions
Anemia
Interventions
placebo, epoetin alpha, Niferex
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
60 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Cranbury, New Jersey • East Brunswick, New Jersey
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Conditions
Preterm Infants
Interventions
three times weekly Epo, weekly Epo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
7 Days to 100 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Intraventricular Hemorrhage of Prematurity
Interventions
MLT+EPO, Placebo
Combination Product · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Hours to 2 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
St. Petersburg, Florida • Baltimore, Maryland
Conditions
Iron Deficiency Anemia
Interventions
Sodium Ferric Gluconate Complex, Oral Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more